Inhibikase Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.91
- Today's High:
- $2.14
- Open Price:
- $2.06
- 52W Low:
- $1.91
- 52W High:
- $6.9438
- Prev. Close:
- $2.1
- Volume:
- 46350
Company Statistics
- Market Cap.:
- $10.54 million
- Book Value:
- 3.679
- Revenue TTM:
- $251788
- Operating Margin TTM:
- -7850.03%
- Gross Profit TTM:
- $-8258499
- Profit Margin:
- 0%
- Return on Assets TTM:
- -43.85%
- Return on Equity TTM:
- -77.72%
Company Profile
Inhibikase Therapeutics Inc had its IPO on 2020-12-23 under the ticker symbol IKT.
The company operates in the Healthcare sector and Biotechnology industry. Inhibikase Therapeutics Inc has a staff strength of 6 employees.
Stock update
Shares of Inhibikase Therapeutics Inc opened at $2.06 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.91 - $2.14, and closed at $1.96.
This is a -6.67% slip from the previous day's closing price.
A total volume of 46,350 shares were traded at the close of the day’s session.
In the last one week, shares of Inhibikase Therapeutics Inc have slipped by -0.51%.
Inhibikase Therapeutics Inc's Key Ratios
Inhibikase Therapeutics Inc has a market cap of $10.54 million, indicating a price to book ratio of 0.4918 and a price to sales ratio of 219.6323.
In the last 12-months Inhibikase Therapeutics Inc’s revenue was $251788 with a gross profit of $-8258499 and an EBITDA of $-18121884. The EBITDA ratio measures Inhibikase Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Inhibikase Therapeutics Inc’s operating margin was -7850.03% while its return on assets stood at -43.85% with a return of equity of -77.72%.
In Q2, Inhibikase Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 1676.7%.
Inhibikase Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-4.3 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Inhibikase Therapeutics Inc’s profitability.
Inhibikase Therapeutics Inc stock is trading at a EV to sales ratio of 2.748 and a EV to EBITDA ratio of 0.7333. Its price to sales ratio in the trailing 12-months stood at 219.6323.
Inhibikase Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $22.35 million
- Total Liabilities
- $2.73 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Inhibikase Therapeutics Inc ended 2024 with $22.35 million in total assets and $0 in total liabilities. Its intangible assets were valued at $22.35 million while shareholder equity stood at $19.46 million.
Inhibikase Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $2.73 million in other current liabilities, 5291.00 in common stock, $-58127586.00 in retained earnings and $0 in goodwill. Its cash balance stood at $1.91 million and cash and short-term investments were $20.94 million. The company’s total short-term debt was $147,966 while long-term debt stood at $0.
Inhibikase Therapeutics Inc’s total current assets stands at $21.98 million while long-term investments were $0 and short-term investments were $19.03 million. Its net receivables were $79604.00 compared to accounts payable of $754146.00 and inventory worth $425229.00.
In 2024, Inhibikase Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Inhibikase Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $1.96
- 52-Week High
- $6.9438
- 52-Week Low
- $1.91
- Analyst Target Price
- $27
Inhibikase Therapeutics Inc stock is currently trading at $1.96 per share. It touched a 52-week high of $6.9438 and a 52-week low of $6.9438. Analysts tracking the stock have a 12-month average target price of $27.
Its 50-day moving average was $2.46 and 200-day moving average was $3.48 The short ratio stood at 1.23 indicating a short percent outstanding of 0%.
Around 2242.7% of the company’s stock are held by insiders while 2137.2% are held by institutions.
Frequently Asked Questions About Inhibikase Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson’s disease and related disorders. Its lead product candidate is IkT-148009, a small molecule Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson’s disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, University of Bordeaux, and Michigan State University, as well as University of California; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.